Chemed Corporation $CHE Position Increased by Sunburst Financial Group LLC

Sunburst Financial Group LLC increased its position in shares of Chemed Corporation (NYSE:CHE) by 46.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 671 shares of the company’s stock after acquiring an additional 213 shares during the period. Sunburst Financial Group LLC’s holdings in Chemed were worth $327,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. HM Payson & Co. purchased a new stake in shares of Chemed during the first quarter worth $30,000. SVB Wealth LLC purchased a new stake in shares of Chemed during the first quarter worth $30,000. WPG Advisers LLC purchased a new stake in shares of Chemed during the first quarter worth $32,000. Creekmur Asset Management LLC bought a new position in Chemed during the second quarter valued at about $28,000. Finally, Geneos Wealth Management Inc. lifted its position in shares of Chemed by 330.4% in the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock worth $61,000 after buying an additional 76 shares during the last quarter. 95.85% of the stock is currently owned by hedge funds and other institutional investors.

Chemed Stock Up 2.2%

CHE stock opened at $440.80 on Tuesday. Chemed Corporation has a twelve month low of $408.42 and a twelve month high of $623.60. The company has a market cap of $6.42 billion, a PE ratio of 23.31, a price-to-earnings-growth ratio of 2.69 and a beta of 0.43. The business’s 50-day simple moving average is $447.38 and its 200 day simple moving average is $491.17.

Chemed (NYSE:CHE) last released its earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). Chemed had a return on equity of 25.89% and a net margin of 11.02%.The firm had revenue of $624.90 million for the quarter, compared to analyst estimates of $626.04 million. During the same period last year, the business earned $5.64 earnings per share. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. On average, equities research analysts anticipate that Chemed Corporation will post 21.43 EPS for the current year.

Insider Transactions at Chemed

In related news, CEO Kevin J. Mcnamara sold 3,000 shares of Chemed stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $461.28, for a total transaction of $1,383,840.00. Following the sale, the chief executive officer directly owned 96,197 shares of the company’s stock, valued at $44,373,752.16. This trade represents a 3.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Patrick P. Grace sold 150 shares of Chemed stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total value of $69,508.50. Following the sale, the director directly owned 3,397 shares in the company, valued at approximately $1,574,135.83. This trade represents a 4.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CHE. Bank of America reduced their price target on Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a research report on Wednesday, September 10th. Oppenheimer reduced their price target on Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a research report on Thursday, July 31st. Zacks Research raised Chemed from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 30th. Royal Bank Of Canada reduced their price target on Chemed from $640.00 to $589.00 and set an “outperform” rating for the company in a research report on Thursday, July 31st. Finally, Jefferies Financial Group raised Chemed from a “hold” rating to a “buy” rating and boosted their price target for the stock from $490.00 to $550.00 in a research report on Tuesday, September 2nd. Four equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $578.50.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.